Veterinary Oncology Market, by Animal Type (Companion Animal (Equine, Canine, and Feline), and Livestock Animal), by Therapy Type (Chemotherapy, Combination Therapy, Immunotherapy, and Targeted Therapy), by Mode of Administration (Oral and Intravenous), b

Veterinary Oncology Market, by Animal Type (Companion Animal (Equine, Canine, and Feline), and Livestock Animal), by Therapy Type (Chemotherapy, Combination Therapy, Immunotherapy, and Targeted Therapy), by Mode of Administration (Oral and Intravenous), by Application (Canine Lymphoma, Osteosarcoma (OSA), Mast Cell Cancer, Melanoma, and Multiple Myeloma), by Distribution Channel (Hospital Pharmacies, Government Agencies, and Retail Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Veterinary oncology is subspecialty of veterinary medicine that deals with the diagnosis and treatment of cancer in animals. With emerging technologies, the use of biotechnology products in veterinary medicines is increasing. Despite the costs that many times accompany the development of novel biotechnological products, recombinant virus vector vaccines, recombinant proteins such as bioactive cytokines and immunotherapeutic allergens, therapeutic antibodies, and oncolytic viruses are the result of advancements in biotechnology for veterinary medicines. The benefits associated with using biotechnology products are large-scale production, reduced costs, long-term action, and multiple antigen vaccines.
Market Dynamics
Increasing prevalence of veterinary cancer is expected to boost the global veterinary oncology market growth during the forecast period. For instance, according to the Veterinary Cancer Society, in 2016, cancer is the leading cause of death in 47% of dogs diagnosed with cancer over the age of 10 years; and 32% of cats, where Feline Leukaemia Virus (FeLV) is one of the leading cause of lymphoma in cats. Moreover, according to the Animal Cancer Foundation in 2015, around 6 million new cancer cases in dogs and cats are recorded, annually, in the U.S., of which one-third of all tumors in dogs are skin tumors, while around 20% are mast cell tumors.
However, adverse effects associated with chemotherapies, immunotherapies, and targeted therapies such as diarrhoea, anorexia, decreased appetite, lethargy, neutropenia, emesis, lameness, severe weight loss, and musculoskeletal disorder are major factors restraining the veterinary oncology market growth.
Key features of the study:
This report provides in-depth analysis of the global veterinary oncology market, market size (US$ Mn), and compound annual growth rate (CAGR %) during the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players operating in this market
It profiles key players in the global veterinary oncology market based on the following parameters–company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include, Zoetis Inc., Elanco, AB Science, Boehringer Ingelheim International GmbH, Zenoaq, VetDC, Morphogenesis, Inc., Karyopharm Therapeutics, Inc., Regeneus Ltd., AdvaVet, Inc., and Rhizen Pharmaceutical SA
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global veterinary oncology market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for global veterinary oncology market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:
Global Veterinary Oncology Market, By Animal Type:
Companion Animal
Equine
Canine
Feline
Livestock Animal
Global Veterinary Oncology Market, By Therapy Type:
Chemotherapy
Combination Therapy
Immunotherapy
Targeted Therapy
Global Veterinary Oncology Market, By Mode of Administration:
Oral
Intravenous
Global Veterinary Oncology Market, By Application:
Canine Lymphoma
Osteosarcoma (OSA)
Mast Cell Cancer
Melanoma
Multiple Myeloma
Global Veterinary Oncology Market, By Distribution Channel:
Hospital Pharmacies
Government Agencies
Retail Pharmacies
Global Veterinary Oncology Market, By Region:
North America
By Country:
U.S.
Canada
By Animal Type:
Companion Animal
Equine
Canine
Feline
Livestock Animal
By Therapy Type:
Chemotherapy
Combination Therapy
Immunotherapy
Targeted Therapy
By Mode of Administration:
Oral
Intravenous
By Application:
Canine Lymphoma
Osteosarcoma (OSA)
Mast Cell Cancer
Melanoma
Multiple Myeloma
By Distribution Channel:
Hospital Pharmacies
Government Agencies
Retail Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Animal Type:
Companion Animal
Equine
Canine
Feline
Livestock Animal
By Therapy Type:
Chemotherapy
Combination Therapy
Immunotherapy
Targeted Therapy
By Mode of Administration:
Oral
Intravenous
By Application:
Canine Lymphoma
Osteosarcoma (OSA)
Mast Cell Cancer
Melanoma
Multiple Myeloma
By Distribution Channel:
Hospital Pharmacies
Government Agencies
Retail Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Animal Type:
Companion Animal
Equine
Canine
Feline
Livestock Animal
By Therapy Type:
Chemotherapy
Combination Therapy
Immunotherapy
Targeted Therapy
By Mode of Administration:
Oral
Intravenous
By Application:
Canine Lymphoma
Osteosarcoma (OSA)
Mast Cell Cancer
Melanoma
Multiple Myeloma
By Distribution Channel:
Hospital Pharmacies
Government Agencies
Retail Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Animal Type:
Companion Animal
Equine
Canine
Feline
Livestock Animal
By Therapy Type:
Chemotherapy
Combination Therapy
Immunotherapy
Targeted Therapy
By Mode of Administration:
Oral
Intravenous
By Application:
Canine Lymphoma
Osteosarcoma (OSA)
Mast Cell Cancer
Melanoma
Multiple Myeloma
By Distribution Channel:
Hospital Pharmacies
Government Agencies
Retail Pharmacies
Middle East
By Country/Region:
GCC
Israel
Rest of Middle East
By Animal Type:
Companion Animal
Equine
Canine
Feline
Livestock Animal
By Therapy Type:
Chemotherapy
Combination Therapy
Immunotherapy
Targeted Therapy
By Mode of Administration:
Oral
Intravenous
By Application:
Canine Lymphoma
Osteosarcoma (OSA)
Mast Cell Cancer
Melanoma
Multiple Myeloma
By Distribution Channel:
Hospital Pharmacies
Government Agencies
Retail Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Animal Type:
Companion Animal
Equine
Canine
Feline
Livestock Animal
By Therapy Type:
Chemotherapy
Combination Therapy
Immunotherapy
Targeted Therapy
By Mode of Administration:
Oral
Intravenous
By Application:
Canine Lymphoma
Osteosarcoma (OSA)
Mast Cell Cancer
Melanoma
Multiple Myeloma
By Distribution Channel:
Hospital Pharmacies
Government Agencies
Retail Pharmacies
Company Profiles
Zoetis Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Elanco
AB Science
Boehringer Ingelheim International GmbH
Zenoaq
VetDC
Morphogenesis, Inc.
Karyopharm Therapeutics, Inc.
Regeneus Ltd.
AdvaVet, Inc.
Rhizen Pharmaceutical SA
“*” marked represents similar segmentation in other categories in the respective section.